Table 3 LE and HL Reference . Age... | American Society of Hematology

Table 3

LE and HL

Reference	Age (y)/gender	Delay* (months)	Type (stage)	Antibody	Treatment	Outcome
18	15/F	4-6	Unknown	ND	Oncological	Full recovery
19	36/M	9	NS (IV)	ND	Oncological, steroids	No improvement
20	33/M	0	NS (IV)	ND	Oncological	Full recovery
21	23/M	10	NS (III)	ND	Steroids,† Oncological	Full recovery
22	13/F	?	NS (?)	ND	Oncological	No improvement
23	53/F	6	NS (II)	Negative‡	Oncological	Full recovery
24	42/M	52	MC (II)	ND	Oncological	No improvement
25	69/F	6	MC (II)	Negative‡	Oncological	Unknown
26	61/M	0	MC (III)	Hu‡	Oncological	Full recovery
27	49/M	0§	NS (?)	NMDAR	Steroids, IVIG, PLEX, oncological	Partial improvement
16	46/F	0	? (III)	mGluR5	Steroids, oncological	Full recovery
28	62/F	?	? (I)	Hu‡,¶	None	Full recovery
29	35/M	6	NS (II)	mGluR5	Oncological	Full recovery

Reference	Age (y)/gender	Delay* (months)	Type (stage)	Antibody	Treatment	Outcome
18	15/F	4-6	Unknown	ND	Oncological	Full recovery
19	36/M	9	NS (IV)	ND	Oncological, steroids	No improvement
20	33/M	0	NS (IV)	ND	Oncological	Full recovery
21	23/M	10	NS (III)	ND	Steroids,† Oncological	Full recovery
22	13/F	?	NS (?)	ND	Oncological	No improvement
23	53/F	6	NS (II)	Negative‡	Oncological	Full recovery
24	42/M	52	MC (II)	ND	Oncological	No improvement
25	69/F	6	MC (II)	Negative‡	Oncological	Unknown
26	61/M	0	MC (III)	Hu‡	Oncological	Full recovery
27	49/M	0§	NS (?)	NMDAR	Steroids, IVIG, PLEX, oncological	Partial improvement
16	46/F	0	? (III)	mGluR5	Steroids, oncological	Full recovery
28	62/F	?	? (I)	Hu‡,¶	None	Full recovery
29	35/M	6	NS (II)	mGluR5	Oncological	Full recovery

IVIG, intravenous immunoglobulins; MC, mixed cellularity; ND, not done; NS, nodular sclerosis; PLEX, plasma exchange.

Delay between onset of LE and HL diagnosis.

No improvement.

Antibodies to surface antigens were not tested.

At relapse.

CSF negative.